ClinicalTrials.gg
RecruitingNCT06593327STRONG-DMUpdated Sep 29, 2026

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

An interventional study of Intensive Prevention Strategy in Type 2 Diabetes, Diabetic Cardiomyopathy and Heart Failure, sponsored by University of Texas Southwestern Medical Center. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Sep 29, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Texas Southwestern Medical Center.

Planned enrollment
4th of 19
300 · median 120
Started
2025
the only one that year
No phase
11 of 22
3 open now
Registered
22nd of 22
by date

Among the 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Diabetes Mellitus, Type 2 by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.

Read the detailed description

Primary care providers will be randomized to receive notifications via the electronic health record if any patients with diabetes have high heart failure risk based on a combination of clinical risk scores(WATCH-DM), and biomarkers (NT-proBNP). Providers will be provided recommendation to initiate evidence based therapies (SGLT2 inhibitors, GLP1 agonists, non-steroidal MRA) , obtain expert e-consultation, or refer the patient to a cardiometabolic risk management program.

03

Conditions studied

  • Type 2 Diabetes
  • Diabetic Cardiomyopathy
  • Heart Failure
  • Cardiometabolic Diseases

Keywords

  • Pragmatic Clinical Trial
  • Heart Failure
  • Cardiovascular Prevention
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary Care Provider that sees diabetes patients in clinic

Exclusion criteria

Exclusion Criteria:

  • Provider does not see patients with Diabetes
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Risk Assessment and Intensive Prevention Strategy

    Primary care providers (PCP) randomized to the Risk Assessment and Intensive Prevention Strategy Arm will receive notification if any patients with diabetes under their care have high heart failure risk based on clinical or biomarker scores. Providers will receive recommendations, option for e-consultation, and referral to cardiometabolic risk management program.

    Behavioral: Intensive Prevention Strategy

  • No intervention
    Usual Care

    Primary care providers randomized to the Usual care arm will not receive any notifications about patients with diabetes and their HF risk assessment.

Interventions

  • BehavioralIntensive Prevention Strategy

    Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.

06

What researchers measure

Primary outcomes

  1. Incident Heart Failure or All-cause death

    Incident Heart Failure (based on electronic health record International Classification of Diseases codes) or all-cause death. This will be assessed via retrospective chart review.

    Time frame: 2-year follow-up

Secondary outcomes

  1. Prescription Rates of SGLT2i

    Counts of SGLT2 inhibitor prescriptions filled

    Time frame: 6-months from electronic health record alert.

  2. Prescription Rate of Finerenone

    Counts of Finerenone prescriptions

    Time frame: 6-months from electronic health record alert.

  3. Prescription Rate of GLP1

    Counts of GLP1 prescription

    Time frame: 6-months from electronic health record alert.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 34 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Feb 10, 2025
Primary completionEst.
Dec 10, 2027
CompletionEst.
Dec 15, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Parkland Health & Hospital System (PHHS) · Dallas, United States
  • Baylor Scott and White - Health System · Dallas, United States
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    2 sites added
    Show 2 added (2 United States)
    • Parkland Health & Hospital System (PHHS) · Dallas, United States
    • Baylor Scott and White - Health System · Dallas, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06593327
Responsible party
Ambarish Pandey (Associate Professor of Internal Medicine, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 19, 2024
Start date
Feb 10, 2025
Primary completion
Dec 10, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Ambarish Pandey, MD
Contact
ambarish.pandey@utsouthwestern.edu
617-869-8957
VINAYAK SUBRAMANIAN, MD
Contact
2114-645-9868

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion